To evaluate the effectiveness of the Shamir Myopia Control lens in slowing myopia progression in children aged 6-13 over 24 months.
Key Findings:
The Shamir Myopia Control lens group showed a 26% reduction in spherical equivalent refraction (SER) progression compared to the control group (0.76 D vs 1.03 D, p < 0.05), indicating a clinically meaningful impact.
Axial length elongation was reduced by 34% in the Shamir lens group compared to the control group (0.33 mm vs 0.50 mm, p < 0.01).
Both groups reported high satisfaction with their visual experience and compliance with lens wear.
Interpretation:
The Shamir Myopia Control lens effectively slows myopia progression in children, demonstrating significant reductions in both SER and axial length elongation over 24 months.
Limitations:
High dropout rate (38%) due to various reasons, including external factors like the October 7 attack, which may have influenced participant retention.
Potential bias in self-reported comfort and satisfaction measures.
Conclusion:
The study supports the use of the Shamir Myopia Control lens as a viable option for managing myopia progression in children, with significant clinical benefits observed over two years, suggesting avenues for future research.
Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia
